Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu, Z., Wang, C., Sitkoff, D., Cheadle, N.L., Xu, S., Muckelbauer, J.K., Adam, L.P., Wexler, R.R., Quan, M.L.(2020) Bioorg Med Chem Lett 30: 127474-127474
- PubMed: 32805407 
- DOI: https://doi.org/10.1016/j.bmcl.2020.127474
- Primary Citation of Related Structures:  
7JNT - PubMed Abstract: 
A novel series of 5H-chromeno[3,4-c]pyridine, 6H-isochromeno[3,4-c]pyridine and 6H-isochromeno[4,3-d]pyrimidine derivatives as dual ROCK1 and ROCK2 inhibitors is described. Optimization led to compounds with sub-nanomolar inhibitory affinity for both kinases and excellent kinome selectivity. Compound 19 exhibited ROCK1 and ROCK2 IC 50 of 0.67 nM and 0.18 nM respectively.
Organizational Affiliation: 
Research & Early Development, Bristol Myers Squibb, P.O. Box 5400, Princeton, NJ 08543-5400, USA. Electronic address: zilun.hu@bms.com.